Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
6
×
national blog main
new york blog main
san diego blog main
6
×
san diego top stories
boston blog main
boston top stories
national top stories
new york top stories
biotech
clinical trials
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
drugs
indiana blog main
indiana top stories
intercept pharmaceuticals
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
celgene
deals
fda
investing
liver
nash
new york
nonalcoholic steatohepatitis
obeticholic acid
What
disease
6
×
drug
6
×
approved
liver
bio
fatty
fda
known
medicine
medicines
nash
race
roundup
year
advanced
ago
akcea
alnylam
alnylam’s
alzheimer's
amyloidosis
approval
attr
available
bacteria
bad
battle
bff
biopharma
brain
business
cancer
case
companies
company
conference
data
deals
debilitating
devoted
Language
Current search:
disease
×
drug
×
" san diego blog main "
×
" life sciences "
×
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections